These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 39398610)

  • 1. Baseline absolute lymphocyte count as a prognostic indicator in advanced or metastatic breast cancer: a systematic review and meta-analysis.
    Xia G; Zhang Z; Jing S; Liu W
    Am J Transl Res; 2024; 16(9):5049-5062. PubMed ID: 39398610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of absolute lymphocyte count and neutrophil-to-lymphocyte ratio for patients with metastatic breast cancer: a systematic review and meta-analysis.
    Sang B; Fan Y; Wang X; Dong L; Gong Y; Zou W; Zhao G; He J
    Front Oncol; 2024; 14():1360975. PubMed ID: 38515567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types.
    Morisaki T; Kashiwagi S; Asano Y; Goto W; Takada K; Ishihara S; Shibutani M; Tanaka H; Hirakawa K; Ohira M
    World J Surg Oncol; 2021 Nov; 19(1):324. PubMed ID: 34775950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
    Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
    BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
    Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
    Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
    Watanabe J; Saito M; Horimoto Y; Nakamoto S
    Breast Cancer Res Treat; 2020 May; 181(1):211-220. PubMed ID: 32249370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.
    Tan S; Zheng Q; Zhang W; Zhou M; Xia C; Feng W
    Front Immunol; 2024; 15():1408700. PubMed ID: 39050856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
    Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
    Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
    Takahashi M; Inoue K; Mukai H; Yamanaka T; Egawa C; Miyoshi Y; Sakata Y; Muramoto K; Ikezawa H; Matsuoka T; Tsurutani J
    Breast Cancer; 2021 Jul; 28(4):945-955. PubMed ID: 33677779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib.
    Emile G; Penager S; Levy C; Johnson A; Allouache D; Lequesne J; Hrab I; Segura C; Morel A; Gunzer K; Faveyrial A; Cherifi F; Da Silva A
    Oncol Lett; 2022 Jan; 23(1):25. PubMed ID: 34868362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
    Tokunaga E; Miyoshi Y; Dozono K; Kawaguchi T; Toi M
    Oncologist; 2024 Mar; 29(3):e319-e329. PubMed ID: 37971418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study.
    Sawa A; Bando H; Kamohara R; Takeuchi N; Terasaki A; Okazaki M; Iguchi-Manaka A; Hara H
    Oncology; 2022; 100(11):591-601. PubMed ID: 36099888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Kanaoka H; Nagahashi M; Atake Y; Hattori A; Bun A; Fukui R; Ozawa H; Fujimoto Y; Higuchi T; Natori K; Imamura M; Murase K; Takatsuka Y; Miyoshi Y
    Anticancer Res; 2022 Oct; 42(10):4867-4878. PubMed ID: 36192009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit.
    Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T
    Anticancer Res; 2021 Jun; 41(6):3109-3119. PubMed ID: 34083304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of Prognostic Factors Considering Absolute Lymphocyte Count of Metastatic Breast Cancer Patients with Eribulin Mesylate Therapy-A Retrospective Study in a Single Institution].
    Ueda Y; Makino Y; Hidaka H; Nakamura T; Beppu K; Ohuchida J; Odate S; Terasaka S; Nishida T; Yoshida M; Kimura R; Shingaki K; Nakanishi Y; Inomata M; Mine Y; Katayose K; Marutsuka K; Otomo N
    Gan To Kagaku Ryoho; 2022 Nov; 49(11):1229-1232. PubMed ID: 36412026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients.
    Koyama Y; Kawai S; Uenaka N; Okazaki M; Asaoka M; Teraoka S; Ueda AI; Miyahara K; Kawate T; Kaise H; Yamada K; Ishikawa T
    Cancer Diagn Progn; 2021; 1(5):435-441. PubMed ID: 35403160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.